Doxorubicine and Nanodoxorubicine Impact on the Life Expectancy of Rats in the Presence of an Experimental Zajdel Hepatoma

The aim of the research was to study the impact of doxorubicin and nanodoxorubicine on the life expectancy of rats in the presence of an experimental Zajdel hepatoma. A series of experiments was carried out on 120 rats weighing 170-200 g. The introduction of nanodoxorubicine in rats after the development of Zajdel ascitic hepatoma decreased the average level of ascites. The average life expectancy increased by 46%, which proves a positive oncostatic effect of the drug.